Windtree Therapeutics Stock Fundamentals
| WINT Stock | USD 2.05 0.01 0.49% |
Windtree Therapeutics fundamentals help investors to digest information that contributes to Windtree Therapeutics' financial success or failures. It also enables traders to predict the movement of Windtree Stock. The fundamental analysis module provides a way to measure Windtree Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Windtree Therapeutics stock.
Windtree |
Windtree Therapeutics Company Shares Owned By Institutions Analysis
Windtree Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Windtree Therapeutics Shares Owned By Institutions | 0.59 % |
Most of Windtree Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Windtree Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 0.59% of Windtree Therapeutics are shares owned by institutions. This is 98.68% lower than that of the Biotechnology sector and 98.76% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 98.5% higher than that of the company.
Windtree Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Windtree Therapeutics's current stock value. Our valuation model uses many indicators to compare Windtree Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Windtree Therapeutics competition to find correlations between indicators driving Windtree Therapeutics's intrinsic value. More Info.Windtree Therapeutics is rated third in return on equity category among its peers. It is rated first in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Windtree Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Windtree Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Windtree Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Windtree Therapeutics could also be used in its relative valuation, which is a method of valuing Windtree Therapeutics by comparing valuation metrics of similar companies.Windtree Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Windtree Fundamentals
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 1.25 M | ||||
| Shares Outstanding | 8.75 M | ||||
| Shares Owned By Insiders | 0.27 % | ||||
| Shares Owned By Institutions | 0.59 % | ||||
| Number Of Shares Shorted | 2.87 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.35 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (20.16 M) | ||||
| Net Income | (20.29 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 16.83 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 5.90 X | ||||
| Cash Flow From Operations | (13.44 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (19.03) X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 13 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 4.92 M | ||||
| Total Asset | 32.41 M | ||||
| Retained Earnings | (844.82 M) | ||||
| Working Capital | 1.38 M | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
| Net Asset | 32.41 M |
About Windtree Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Windtree Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Windtree Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Windtree Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Windtree Therapeutics, Inc. is a subsidiary of Lees Pharmaceutical Holdings Limited. Windtree Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.